TGTX Q2 2020 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000+0.0% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$51M-133802.6% margin

Net Income

-$53M-139168.4% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$295M

Total Liabilities

$100M

Stockholders' Equity

$194M

Cash & Equivalents

$261M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,000	+0.0%
Gross Profit	$38,000	$38,000	+0.0%
Operating Income	-$51M	-$36M	-43.0%
Net Income	-$53M	-$36M	-46.0%